Day: July 9, 2025

Extends patent exclusivity period an additional 6 years once granted SOLANA BEACH, Calif., July 09, 2025 (GLOBE NEWSWIRE) — Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a U.S. patent application covering the use of GIMOTI® in patients with moderate to severe symptoms of gastroparesis. The allowed application is a continuation of U.S. Patent No. 11,517,545, and further expands Evoke’s intellectual property estate around intranasal metoclopramide. Upon issuance, the patent will be expected to expire in December 2036 and the company intends to list the patent in the...

RUTHERFORD, N.J., July 09, 2025 (GLOBE NEWSWIRE) — Blue Foundry Bancorp (NASDAQ: BLFY) (the “Company”), the holding company for Blue Foundry Bank, announced that on the morning of Wednesday, July 30, 2025 it will release financial results for the quarter ended June 30, 2025. A copy of the earnings release will be available on the Company’s website, https://ir.bluefoundrybank.com/, in the “News” section and on the SEC’s website, https://www.sec.gov/. Representatives of the Company will hold a conference call for investors and analysts on Wednesday, July 30, 2025 at 11:00AM (ET) to discuss Second Quarter 2025 Earnings. Blue Foundry Bancorp will address live questions from analysts. The conference call will be recorded and will be available on the Company’s website for one month. We encourage participants to pre-register to listen...

System includes AT&T® 5G technology for seamless Maritime Domain Awareness MONROE TOWNSHIP, N.J., July 09, 2025 (GLOBE NEWSWIRE) — Ocean Power Technologies, Inc. (NYSE American: OPTT) (“OPT” or the “Company”), a leader in innovative and cost-effective low-carbon marine power, data, and service solutions, today announced the successful installation of its previously contracted PowerBuoy® system for the Naval Postgraduate School (NPS). The full system, now deployed in Monterey Bay, integrates AT&T® 5G technology and advanced subsea sensors into OPT’s latest PowerBuoy® equipped with its proprietary Merrows™ suite—designed for AI-capable, seamless Maritime Domain Awareness (MDA) integration across manned and unmanned platforms. The PowerBuoy® will provide continuous, autonomous monitoring and data collection in one...

Eye-Net’s V2X collision prevention technology is scheduled for live trial with 10,000 participants in the fourth quarter of 2025 Ness Ziona, Israel, July 09, 2025 (GLOBE NEWSWIRE) — Foresight Autonomous Holdings Ltd. (Nasdaq and TASE: FRSX) (“Foresight” or the “Company”), an innovator in 3D perception systems, announced that its wholly-owned subsidiary, Eye-Net Mobile Ltd. (“Eye-Net”), has successfully completed the first phase of a landmark mobility trial in Bordeaux, France. The trial involved a mobile app developed by Orange S.A., one of the world’s leading telecommunications companies, alongside other urban applications as part of Eye-Net’s collaboration with Software République. This follows the agreement with Software République to enable smart mobility solutions for efficient urban mobility in France, as announced by the...

Aalst, Belgium, July 9, 2025 – Ontex Group NV [EURONEXT: ONTEX], a leading international developer and producer of personal care solutions, is advancing its sustainability journey with the introduction of bio-based superabsorbent polymers (bioSAP) in its diapers, with an initial rollout in selected Moltex Pure and Nature products. This new material will gradually and incrementally replace virgin fossil-based plastic SAP in the core absorbent component, helping lower the carbon footprint of the product while maintaining performance. This step aligns with Ontex’s commitment to embedding good, scalable sustainability practices into every product.  SAP (superabsorbent polymer) is essential to diaper performance yet is traditionally made from fossil-based plastic. It is also one of the most carbon-intensive components in hygiene products. The...

NEEDHAM, Mass., July 09, 2025 (GLOBE NEWSWIRE) — Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that the Company was added to multiple Russell indexes as part of the 2025 Russell US Indexes annual reconstitution, which became effective at the open of the U.S. equity markets on June 30, 2025. Candel was added to the Russell 2500 Value® Index, Russell Small Cap Value® Index, Russell 2000 Value® Index, Russell Microcap Value® Index, and Russell 3000E® Value Index. Additionally, the Company maintained its membership in the broad-market Russell 3000® Index, which it first joined in 2024. “Candel’s inclusion across multiple Russell Value® indexes represents an important...

ROCKVILLE, Md., July 09, 2025 (GLOBE NEWSWIRE) — MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it will release financial results for the second quarter 2025 after the U.S. market close on Wednesday, August 6th, 2025. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time. Earnings Conference Call DetailsInvestors interested in listening to the conference call are required to register online. It is recommended to register at least a day in advance. A live and archived webcast of the event will be available on the “Events” section of the MaxCyte website at https://investors.maxcyte.com/. About MaxCyte At...

Article Indicates that Inhibition of PP2A Enhances Immunotherapy Responsewith LIXTE’s Proprietary Compound LB100 PASADENA, Calif., July 09, 2025 (GLOBE NEWSWIRE) — LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced that the medical journal Nature has published findings by a team of physician-scientists that validate LIXTE’s ongoing clinical trials with its proprietary compound LB100 for Ovarian and Colorectal cancers (https://www.nature.com/articles/s41586-025-09203-8). A team led by principal investigator Amir Jazaeri, MD, professor of Gynecologic Oncology and Reproductive Medicine at The University of Texas MD Anderson Cancer Center, studied survival outcomes of Ovarian Clear Cell Carcinoma (OCCC) patients treated with immune checkpoint...